BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 303 filers reported holding BLUEBIRD BIO INC in Q4 2017. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,541 | -5.4% | 507 | +2.4% | 0.00% | – |
| Q2 2023 | $1,629 | +62.6% | 495 | +57.1% | 0.00% | – |
| Q1 2023 | $1,002 | -66.9% | 315 | -27.9% | 0.00% | – |
| Q4 2022 | $3,024 | +51.2% | 437 | +50.7% | 0.00% | – |
| Q3 2022 | $2,000 | +100.0% | 290 | +12.4% | 0.00% | – |
| Q1 2022 | $1,000 | -66.7% | 258 | +2.8% | 0.00% | – |
| Q4 2021 | $3,000 | -40.0% | 251 | 0.0% | 0.00% | – |
| Q3 2021 | $5,000 | -89.4% | 251 | -83.1% | 0.00% | -100.0% |
| Q2 2021 | $47,000 | +9.3% | 1,485 | +3.2% | 0.00% | 0.0% |
| Q1 2021 | $43,000 | -30.6% | 1,439 | +0.8% | 0.00% | -33.3% |
| Q4 2020 | $62,000 | +785.7% | 1,428 | +1080.2% | 0.00% | – |
| Q3 2020 | $7,000 | +40.0% | 121 | +39.1% | 0.00% | – |
| Q2 2020 | $5,000 | +400.0% | 87 | +569.2% | 0.00% | – |
| Q1 2020 | $1,000 | -75.0% | 13 | -74.5% | 0.00% | – |
| Q4 2019 | $4,000 | -98.6% | 51 | -96.9% | 0.00% | -100.0% |
| Q4 2017 | $294,000 | – | 1,653 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 4,282,827 | $13,019,794 | 1.84% |
| Birchview Capital, LP | 455,200 | $1,383,808 | 1.18% |
| PFM Health Sciences, LP | 6,040,934 | $18,364,439 | 0.86% |
| Lion Point Capital, LP | 531,256 | $1,615,018 | 0.72% |
| Endurant Capital Management LP | 251,785 | $765,426 | 0.69% |
| Bleichroeder LP | 900,000 | $2,736,000 | 0.67% |
| Connacht Asset Management LP | 31,634 | $96,167 | 0.57% |
| Granahan Investment Management | 5,137,778 | $15,618,845 | 0.56% |
| Frazier Life Sciences Management, L.P. | 1,709,907 | $5,198,117 | 0.34% |
| Contrarius Investment Management Ltd | 1,308,002 | $3,976 | 0.22% |